Inhibition of MUC1-C Entering Nuclear Suppresses MYC Expression and Attenuates Malignant Growth in Esophageal Squamous Cell Carcinoma

Overview

Journal Onco Targets Ther

Publisher Dove Medical Press

Specialty Oncology

Date 2018 Jul 28

PMID 30050304

Citations 8

Authors

Zhongwei Xin

Gongsun Xin

Mo Shi

Liang Song

Qiang Wang

Bin Jiang

Xiangyan Liu

Affiliations

Soon will be listed here.

Abstract

Background: The mucin 1 (MUC1) heterodimeric protein (N-terminal subunit and C-terminal subunit) is aberrantly overexpressed in esophageal squamous cell carcinoma (ESCC) and has been linked to poor outcomes in this disease. The detailed mechanism(s), however, remains unclear. In this article, we investigate the effects of the MUC1 C-terminal transmembrane subunit (MUC1-C) through the inhibitor GO-201, which inhibits MUC1-C targeting to nuclear.

Patients And Methods: The expression of MUC1-C and MYC in the ESCC samples and cell lines was detected by immunohistochemistry, immunofluorescence and western blotting. MYC mRNA level was determined by using quantitative real-time polymerase chain reaction. In addition, Cell Counting Kit-8, clonogenic assay, transwell assay and tumor xenograft in nude mice assay were utilized to determine the role of MUC1-C in proliferation, invasion and migration of ESCC cells.

Results: The level of MUC1-C in nuclear and MYC in whole cells in the ESCC tissue is significantly higher than that in the noncancerous tissue. Treatment of MUC1-C-overexpressing ESCC cells with GO-201 was associated with downregulation of MYC expression and induction of apoptosis. Besides, in vitro and in vivo assays have both shown that inhibiting MUC1-C targeting to the nucleus by the GO-201 significantly decreased the abilities of proliferation, invasion and migration in ESCC cells.

Conclusion: Our findings suggest that MUC1-C targeting to the nucleus plays an important role in suppressing the malignant growth of ESCC and indicate that MUC1-C is a potential target for the treatment of ESCC.

Citing Articles

Establishment and validation of the prognostic risk model based on the anoikis-related genes in esophageal squamous cell carcinoma.

Cao S, Li M, Cui Z, Li Y, Niu W, Zhu W Ann Med. 2024; 56(1):2418338.

PMID: 39444152 PMC: 11504171. DOI: 10.1080/07853890.2024.2418338.

Interleukin 33 supports squamous cell carcinoma growth via a dual effect on tumour proliferation, migration and invasion, and T cell activation.

Perri G, Vilas Boas V, Nogueira M, Mello Junior E, Coelho A, Posadas E Cancer Immunol Immunother. 2024; 73(6):110.

PMID: 38662248 PMC: 11045681. DOI: 10.1007/s00262-024-03676-8.

Targeting MUC1-C reverses the cisplatin resistance of esophageal squamous cell carcinoma and .

Zhao Y, Wu T, Wang L, Yin B, Shi M, Jiang B Transl Cancer Res. 2022; 10(2):645-655.

PMID: 35116398 PMC: 8799139. DOI: 10.21037/tcr-20-2495.

Evodiamine suppresses non-small cell lung cancer by elevating CD8 T cells and downregulating the MUC1-C/PD-L1 axis.

Jiang Z, Huang J, Xie Y, Zhang Y, Chang C, Lai H J Exp Clin Cancer Res. 2020; 39(1):249.

PMID: 33208183 PMC: 7677782. DOI: 10.1186/s13046-020-01741-5.

MUC1-C in chronic inflammation and carcinogenesis; emergence as a target for cancer treatment.

Kufe D Carcinogenesis. 2020; 41(9):1173-1183.

PMID: 32710608 PMC: 7513951. DOI: 10.1093/carcin/bgaa082.

References

Arvanitis C, Felsher D . Conditional transgenic models define how MYC initiates and maintains tumorigenesis. Semin Cancer Biol. 2006; 16(4):313-7. DOI: 10.1016/j.semcancer.2006.07.012. View

Bretones G, Delgado M, Leon J . Myc and cell cycle control. Biochim Biophys Acta. 2014; 1849(5):506-16. DOI: 10.1016/j.bbagrm.2014.03.013. View

Leng Y, Cao C, Ren J, Huang L, Chen D, Ito M . Nuclear import of the MUC1-C oncoprotein is mediated by nucleoporin Nup62. J Biol Chem. 2007; 282(27):19321-30. DOI: 10.1074/jbc.M703222200. View

Raina D, Agarwal P, Lee J, Bharti A, McKnight C, Sharma P . Characterization of the MUC1-C Cytoplasmic Domain as a Cancer Target. PLoS One. 2015; 10(8):e0135156. PMC: 4534190. DOI: 10.1371/journal.pone.0135156. View

Dang C . MYC on the path to cancer. Cell. 2012; 149(1):22-35. PMC: 3345192. DOI: 10.1016/j.cell.2012.03.003. View

Kufe D . MUC1-C oncoprotein as a target in breast cancer: activation of signaling pathways and therapeutic approaches. Oncogene. 2012; 32(9):1073-81. PMC: 3621754. DOI: 10.1038/onc.2012.158. View

Yin L, Tagde A, Gali R, Tai Y, Hideshima T, Anderson K . MUC1-C is a target in lenalidomide resistant multiple myeloma. Br J Haematol. 2017; 178(6):914-926. PMC: 5591051. DOI: 10.1111/bjh.14801. View

Li J, Xiang S, Zhang Q, Wu J, Tang Q, Zhou J . Combination of curcumin and bicalutamide enhanced the growth inhibition of androgen-independent prostate cancer cells through SAPK/JNK and MEK/ERK1/2-mediated targeting NF-κB/p65 and MUC1-C. J Exp Clin Cancer Res. 2015; 34:46. PMC: 4446835. DOI: 10.1186/s13046-015-0168-z. View

Mizoguchi K, Ishiguro H, Kimura M, Takahashi H, Sakamoto N, Tanaka T . Induction of apoptosis by eicosapentaenoic acid in esophageal squamous cell carcinoma. Anticancer Res. 2014; 34(12):7145-9. View

10.

Li B, Simon M . Molecular Pathways: Targeting MYC-induced metabolic reprogramming and oncogenic stress in cancer. Clin Cancer Res. 2013; 19(21):5835-41. PMC: 3818456. DOI: 10.1158/1078-0432.CCR-12-3629. View

11.

Shi M, Chen D, Yang D, Liu X . CCL21-CCR7 promotes the lymph node metastasis of esophageal squamous cell carcinoma by up-regulating MUC1. J Exp Clin Cancer Res. 2015; 34:149. PMC: 4678529. DOI: 10.1186/s13046-015-0268-9. View

12.

Raina D, Kosugi M, Ahmad R, Panchamoorthy G, Rajabi H, Alam M . Dependence on the MUC1-C oncoprotein in non-small cell lung cancer cells. Mol Cancer Ther. 2011; 10(5):806-16. PMC: 3092019. DOI: 10.1158/1535-7163.MCT-10-1050. View

13.

Yin L, Ahmad R, Kosugi M, Kawano T, Avigan D, Stone R . Terminal differentiation of chronic myelogenous leukemia cells is induced by targeting of the MUC1-C oncoprotein. Cancer Biol Ther. 2010; 10(5):483-91. PMC: 3034602. DOI: 10.4161/cbt.10.5.12584. View

14.

Soucek L, Whitfield J, Martins C, Finch A, Murphy D, Sodir N . Modelling Myc inhibition as a cancer therapy. Nature. 2008; 455(7213):679-83. PMC: 4485609. DOI: 10.1038/nature07260. View

15.

Sagara M, Yonezawa S, Nagata K, Tezuka Y, Natsugoe S, Xing P . Expression of mucin 1 (MUC1) in esophageal squamous-cell carcinoma: its relationship with prognosis. Int J Cancer. 1999; 84(3):251-7. DOI: 10.1002/(sici)1097-0215(19990621)84:3<251::aid-ijc9>3.0.co;2-7. View

16.

Raina D, Ahmad R, Joshi M, Yin L, Wu Z, Kawano T . Direct targeting of the mucin 1 oncoprotein blocks survival and tumorigenicity of human breast carcinoma cells. Cancer Res. 2009; 69(12):5133-41. PMC: 2721222. DOI: 10.1158/0008-5472.CAN-09-0854. View

17.

Beroukhim R, Mermel C, Porter D, Wei G, Raychaudhuri S, Donovan J . The landscape of somatic copy-number alteration across human cancers. Nature. 2010; 463(7283):899-905. PMC: 2826709. DOI: 10.1038/nature08822. View

18.

Nath S, Mukherjee P . MUC1: a multifaceted oncoprotein with a key role in cancer progression. Trends Mol Med. 2014; 20(6):332-42. PMC: 5500204. DOI: 10.1016/j.molmed.2014.02.007. View

19.

Rajabi H, Kufe D . MUC1-C Oncoprotein Integrates a Program of EMT, Epigenetic Reprogramming and Immune Evasion in Human Carcinomas. Biochim Biophys Acta Rev Cancer. 2017; 1868(1):117-122. PMC: 5548633. DOI: 10.1016/j.bbcan.2017.03.003. View

20.

Ye Q, Yan Z, Liao X, Li Y, Yang J, Sun J . MUC1 induces metastasis in esophageal squamous cell carcinoma by upregulating matrix metalloproteinase 13. Lab Invest. 2011; 91(5):778-87. DOI: 10.1038/labinvest.2011.12. View